Time-dependent ligand-receptor binding kinetics and functionality in a heterodimeric receptor model

dc.contributor.author
Ortiz, A. J.
dc.contributor.author
Martín, V.
dc.contributor.author
Romero, D.
dc.contributor.author
Guillamon, A.
dc.contributor.author
Giraldo, J.
dc.date.accessioned
2024-07-08T13:06:41Z
dc.date.accessioned
2024-09-19T14:35:07Z
dc.date.available
2024-07-08T13:06:41Z
dc.date.available
2024-09-19T14:35:07Z
dc.date.issued
2024-07-01
dc.identifier.uri
http://hdl.handle.net/2072/537704
dc.description.abstract
GPCRs heteromerize both in CNS and non-CNS regions. The cell uses receptor heteromerization to modulate receptor functionality and to provide fine tuning of receptor signaling. In order for pharmacologists to explore these mechanisms for therapeutic purposes, quantitative receptor models are needed. We have developed a timedependent model of the binding kinetics and functionality of a preformed heterodimeric receptor involving two drugs. Two cases were considered: both or only one of the drugs are in excess with respect to the total concentration of the receptor. The latter case can be applied to those situations in which a drug causes unwanted side effects that need to be reduced by decreasing its concentration. The required efficacy can be maintained by the allosteric effects mutually exerted by the two drugs in the two-drug combination system. We discuss this concept assuming that the drug causing unwanted side effects is an opioid and that analgesia is the therapeutic effect. As additional points, allosteric modulation by endogenous compounds and synthetic bivalent ligands was included in the study. Receptor heteromerization offers a mechanistic understanding and quantification of the pharmacological effects elicited by combinations of two drugs at different doses and with different efficacies and cooperativity effects, thus providing a conceptual framework for drug combination therapy.
eng
dc.description.sponsorship
This project has received funding from the European Union’s Horizon2020 research and innovation program under grant agreement No848068. This publication reflects only the authors’ view and the EuropeanCommission is not responsible for any use that may be made of theinformation it contains. This work is partially supported by the grantsPID2020-119136RB-I00, PID-2021-122954NB-I00, PID2022-137708NB-I00 and the Severo Ochoa and María de Maeztu Programsfor Centers and Units of Excellence in R&D (CEX2020-001084-M) fundedby MCIN/AEI/10.13039/501100011033 and by ERDF “A way ofmaking Europe”, and by the AGAUR grant 2021-SGR-01039. AJO isfunded by FPI fellowship (PRE2021-100772) associated to PID2020-119136RB-I00 grant.
dc.format.extent
13 p.
dc.language.iso
eng
dc.publisher
Pergamon-Elsevier Science Ltd
dc.relation.ispartof
Biochemical Pharmacology
dc.rights
L'accés als continguts d'aquest document queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: https://creativecommons.org/licenses/by/4.0/
dc.source
RECERCAT (Dipòsit de la Recerca de Catalunya)
dc.subject.other
Binding kinetics
dc.subject.other
Receptor heterodimerization
dc.subject.other
Drug combination therapy
dc.subject.other
Mathematical modeling
dc.subject.other
Dynamical systems
dc.title
Time-dependent ligand-receptor binding kinetics and functionality in a heterodimeric receptor model
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
dc.embargo.terms
cap
dc.identifier.doi
10.1016/j.bcp.2024.116299
dc.rights.accessLevel
info:eu-repo/semantics/openAccess


Documentos

Time-dependentLigand-receptor.pdf

1.945Mb PDF

Este ítem aparece en la(s) siguiente(s) colección(ones)

CRM Articles [713]